Projects per year
Personal profile
Biography
Dr Sueh-li Lim is a haematologist with interest in all aspects of haematology patient care, encompasing both malignant and non-malignant haematology. Dr Lim completed her clinical haematology training at the Alfred Hospital and Western Health, in addition to laboratory haematology training at Melbourne Pathology. She is passionate about providing patient-focused, holistic care for all patients with haematological disorders.
Her current appointments are at Melbourne Pathology (laboratory haematology), Western Health (clinical haematology), in addition to practicing privately as part of the Melbourne Haematology group
Research area keywords
- Malignant Haematology
- Non-malignant haematology
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Active
-
A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants with Relapsed or Refractory Multiple Myeloma
Lim, S.-L. (Primary Chief Investigator (PCI)) & Kennedy, N. (Project Manager)
22/02/24 → 21/02/26
Project: Research
-
Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma
Zhao, J., Khong, T., Gorniak, M., Khaled, A., McDonald, Z., Reynolds, J., Mithraprabhu, S., Bingham, N., Lim, S., Wong, D., Johnston, A., Motorna, O., Murphy, N., Quach, H., Yang, L. & Spencer, A., Mar 2025, In: Haematologica. 110, 3, p. 764-767 4 p.Research output: Contribution to journal › Letter › Research › peer-review
Open Access1 Citation (Scopus) -
Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registry
Lim, S. L., Wellard, C., Moore, E., Harrison, S. J., Hang, Q., Ho, J., Rajagopal, R. & Spencer, A., May 2024, In: Internal Medicine Journal. 54, 5, p. 773-778 6 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access1 Citation (Scopus) -
Response adaptive salvage treatment with daratumumab–lenalidomide–dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy—ALLG MM21
Lim, S., Reynolds, J., Quach, H., Hutchinson, A., Kerridge, I., Janowski, W., Bergin, K. & Spencer, A., Sept 2024, In: British Journal of Haematology. 205, 3, p. 900-914 15 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy
Lim, S.-L., Reynolds, J., Quach, H., Hutchinson, A., Kerridge, I. H., Estell, J. A., Wallington-Gates, C., Kalff, A., Yuen, F. & Spencer, A., 15 Nov 2022, In: Blood. 140, Supplement 1, p. 10174-10176 3 p.Research output: Contribution to journal › Meeting Abstract › peer-review
-
Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy
Lim, S.-L., Reynolds, J., Quach, H., Hutchinson, A., Kerridge, I. H., Estell, J., Janowski, W., Wallington-Beddoe, C. T., Kalff, A., Yuen, F. & Spencer, A., 23 Nov 2021, In: Blood. 138, Supplement 1, p. 1665 1 p.Research output: Contribution to journal › Meeting Abstract › peer-review
Open Access